Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 2/20 | 0.48 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886429 | 0.92 | TRPC3 (0.45) | NPY5RTRPC3HTR2BTP53LMNA | |
| SCHEMBL2879050 | 0.84 | NPY5R (0.47) | NPY5RTRPC3HTR2BTP53LMNA | |
| SCHEMBL2884445 | 0.83 | NPY5R (0.42) | NPY5RTRPC3TP53LMNA | |
| SCHEMBL2884131 | 0.82 | NPY5R (0.49) | NPY5RHTR2BLMNAUSP30MAPT | |
| SCHEMBL2879048 | 0.76 | HTR2B (0.41) | NPY5RTRPC3HTR2BTP53MAPT | |
| SCHEMBL2884441 | 0.75 | TRPC3 (0.38) | NPY5RTRPC3HTR2BTP53LMNA | |
| SCHEMBL2878853 | 0.74 | NPY5R (0.52) | NPY5RHTR2BLMNAALKBH3MAPT | |
| SCHEMBL2884125 | 0.74 | HTR2B (0.47) | NPY5RHTR2BUSP30 | |
| SCHEMBL2884128 | 0.74 | HTR2B (0.47) | NPY5RHTR2BUSP30 | |
| SCHEMBL2885065 | 0.73 | NPY5R (0.46) | NPY5RHTR2BALKBH3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691860-B2 | Sulfonamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | claimed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | claimed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | claimed |
| US-7691860-B2 | Sulfonamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | MSD K.K. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1719765-A1 | NOVEL SULFONE AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161326-A1 | Novel Sulfone Amide Amide Derivatives | NPY1R, NPY2R, NPY5R | NPY5R 3/4885TRPC3 3127/4885HTR2B 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.